HkeyBio New Platform Launch: AIH, PBC, and IgAN Model Matrix Empowers "One Drug, Multiple Screens" in Autoimmune New Drug R&D

HkeyBio unveiled new preclinical disease model platforms for Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), and IgA Nephropathy (IgAN), integrating standardized rodent models with ongoing non-human primate research. The launch aims to help global drug developers evaluate efficacy, study mechanisms, and identify biomarkers across species, addressing translational gaps that complicate autoimmune disease research. The release notes that regulatory bodies such as the FDA, EMA, and ICH have pressed for better biomarkers and translational strategies to bridge preclinical results with clinical outcomes. The platform supports moving from discovery to IND, enabling cross-species validation and accelerated translational research, as autoimmune disease research increasingly leverages shared immune mechanisms across organs. The announcement positions model richness and translational relevance as critical to efficient R&D in a competitive landscape.